Huang D Y, Osswald H, Vallon V
Department of Pharmacology, University of Tübingen, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1998 Sep;358(3):367-73. doi: 10.1007/pl00005266.
Sodium azide (NaN3, AZ) is a potent inhibitor and uncoupler of oxidative phosphorylation as well as a nitrovasodilator after being converted to nitric oxide (NO). We studied the effect of intratubular application of AZ on loop of Henle reabsorption and tubuloglomerular feedback (TGF) employing renal micropuncture experiments in nephrons with superficial glomeruli of anesthetized Munich-Wistar-Fromter rats. During perfusion of Henle's loop downstream from an obstructing wax block, AZ (3x10(-5) mol/l and 3x10(-4) mol/l) concentration-dependently increased early distal tubular flow rate and sodium and potassium ion concentration (V(ED), [Na+]ED, [K+]ED). In comparison, application of furosemide (10(-4) mol/l), the action of which is restricted to the water-impermeable thick ascending limb of Henle's loop (TALH) and the macula densa, similarly increased [Na+]ED and [K+]ED, but did not affect V(ED). The effect of AZ on loop of Henle reabsorption appeared to be predominantly localized upstream to the TALH since (1) AZ significantly inhibited net fluid reabsorption (the latter being completely abolished at 3x10(-4) mol/l), (2) the effect of AZ on [Na+]ED and [K+]ED could be mimicked by perfusing the Henle's loop at a flow rate that caused a comparable increase in V(ED) (reflecting a comparable load to TALH), and (3) the effects of AZ and furosemide were additive. In spite of the increase in [Na+]ED and [K+]ED, intratubular application of AZ caused a concentration-dependent inhibition of TGF response, the latter being assessed as the fall in early proximal tubular stop flow pressure during perfusion of Henle's loop at increasing flow rate. Like AZ and furosemide, the NO donor sodium nitroprusside (10(-4) mol/l) blunted the TGF response, but in contrast to furosemide or AZ, it caused a minor decrease in V(ED), without changing [Na+]ED or [K+]ED. The inhibitory effect of AZ on TGF was abolished by the NO scavenger carboxy PTIO. In summary, AZ inhibits both reabsorption in the water-permeable segment of Henle's loop and the TGF response. The effect on reabsorption may be linked to metabolic inhibition rather than NO release, whereas the blunted TGF response appears to involve conversion to NO.
叠氮化钠(NaN₃,AZ)是氧化磷酸化的强效抑制剂和解偶联剂,转化为一氧化氮(NO)后还是一种硝基血管扩张剂。我们利用麻醉的慕尼黑 - 威斯塔 - 弗罗特大鼠浅表肾小球肾单位的肾微穿刺实验,研究了肾小管内应用AZ对亨利氏袢重吸收和肾小管 - 肾小球反馈(TGF)的影响。在从阻塞蜡块下游灌注亨利氏袢期间,AZ(3×10⁻⁵mol/L和3×10⁻⁴mol/L)浓度依赖性地增加了早期远端肾小管流速以及钠和钾离子浓度(V(ED)、[Na⁺]ED、[K⁺]ED)。相比之下,应用呋塞米(10⁻⁴mol/L),其作用仅限于亨利氏袢水不通透的厚升支(TALH)和致密斑,同样增加了[Na⁺]ED和[K⁺]ED,但不影响V(ED)。AZ对亨利氏袢重吸收的作用似乎主要定位于TALH的上游,因为(1)AZ显著抑制净液体重吸收(在3×10⁻⁴mol/L时后者被完全消除),(2)以导致V(ED)可比增加的流速灌注亨利氏袢可模拟AZ对[Na⁺]ED和[K⁺]ED的作用(反映对TALH的可比负荷),并且(3)AZ和呋塞米的作用是相加的。尽管[Na⁺]ED和[K⁺]ED增加,但肾小管内应用AZ导致TGF反应浓度依赖性抑制,后者通过在增加流速时灌注亨利氏袢期间早期近端肾小管停流压力的下降来评估。与AZ和呋塞米一样,NO供体硝普钠(10⁻⁴mol/L)减弱了TGF反应,但与呋塞米或AZ不同的是,它导致V(ED)略有下降,而不改变[Na⁺]ED或[K⁺]ED。NO清除剂羧基PTIO消除了AZ对TGF的抑制作用。总之,AZ抑制亨利氏袢水通透段的重吸收和TGF反应。对重吸收的作用可能与代谢抑制而非NO释放有关,而减弱的TGF反应似乎涉及转化为NO。